Loading page
Loading page
Loading substance route
Classified as habit-forming, suggesting potential for psychological dependence, though detailed characterization is lacking due to the substance's limited research history.
Toxicity is not well established due to the substance's short history of human use.
Visual and auditory hallucinations have been reported among the substance's effects, though the frequency and clinical significance of these perceptual disturbances remain poorly characterized.
Flephedrone first appeared on the recreational drug market in 2008, where it was sold online as a designer drug. It was marketed primarily as a replacement for mephedrone, which was gaining popularity during the same period. The substance represents one of the earlier synthetic cathinones to emerge in the designer drug marketplace, and its appearance prompted rapid regulatory responses across multiple jurisdictions, with Denmark becoming one of the first countries to prohibit it by the end of 2008.
Most likely controlled as an analogue or derivative of cathinone under analogue provisions. Legal status may vary by state and territory.
Listed as a controlled substance since October 2015 under national drug control regulations.
Scheduled in the government decree on psychoactive substances banned from the consumer market.
Prohibited since April 2010 under national controlled substances legislation.
Prohibited since April 2010. Possession, production, and supply are criminal offenses.
Controlled since 2017 as an analogue or derivative of cathinone under Brazilian drug legislation.
Prohibited since December 2008. One of the earliest European nations to control flephedrone.
Prohibited since April 2010 under national drug control legislation.
Classified as a narcotic substance since October 2010. Subject to penalties under Swedish narcotics law.
Temporarily placed in Schedule I of the Controlled Substances Act at the federal level. Permanently listed as Schedule I in Florida, Georgia, and Pennsylvania.
12 sources cited